Jane Knochel

AstraZeneca AB R&D
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

PBPK Models for Fetal Drug Exposure: A Critical Assessment of Current Approaches and Regulatory Readiness.

PBPK Models for Fetal Drug Exposure: A Critical Assessment of Current Approaches and Regulatory Readiness.

Journal: Journal of clinical pharmacology
Published: June 08, 2026

Fibroblast activation protein and down-stream effects on its substrates in metabolic dysfunction-associated steatotic liver disease.

Fibroblast activation protein and down-stream effects on its substrates in metabolic dysfunction-associated steatotic liver disease.

Journal: Scandinavian journal of gastroenterology
Published: June 03, 2026

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive Patients.

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive Patients.

Journal: Circulation
Published: May 15, 2026

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.

Journal: Circulation
Published: May 15, 2026

The Advance of In Silico Evidence to Transform Pediatric Drug Development for Rare Diseases.

The Advance of In Silico Evidence to Transform Pediatric Drug Development for Rare Diseases.

Journal: CPT: pharmacometrics & systems pharmacology
Published: October 20, 2025

Tackling High Dimensionality in QSP: Guiding Model Order Reduction With Index Analysis.

Tackling High Dimensionality in QSP: Guiding Model Order Reduction With Index Analysis.

Journal: CPT: pharmacometrics & systems pharmacology
Published: August 01, 2025

Predictive AI in Clinical Pharmacology: A Call to Action to Develop Robust Benchmarking Practices.

Predictive AI in Clinical Pharmacology: A Call to Action to Develop Robust Benchmarking Practices.

Journal: CPT: pharmacometrics & systems pharmacology
Published: July 21, 2025

Transforming Pediatric Rare Disease Drug Development: Enhancing Clinical Trials and Regulatory Evidence With Virtual Patients.

Transforming Pediatric Rare Disease Drug Development: Enhancing Clinical Trials and Regulatory Evidence With Virtual Patients.

Journal: CPT: pharmacometrics & systems pharmacology
Published: May 15, 2025

A Case Study of Model-Informed Drug Development of a Novel PCSK9 Antisense Oligonucleotide. Part 2: Phase 2 to Phase 3.

A Case Study of Model-Informed Drug Development of a Novel PCSK9 Antisense Oligonucleotide. Part 2: Phase 2 to Phase 3.

Journal: CPT: pharmacometrics & systems pharmacology
Published: February 21, 2025

Recent applications of pharmacometrics and systems pharmacology approaches to improve and optimize drug therapy for pregnant and lactating women.

Recent applications of pharmacometrics and systems pharmacology approaches to improve and optimize drug therapy for pregnant and lactating women.

Journal: CPT: pharmacometrics & systems pharmacology
Published: October 13, 2024

AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials.

AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials.

Journal: Journal of hepatology
Published: August 20, 2024

Enhancing inclusivity in clinical trials: Model-informed drug development for pregnant individuals in the era of personalized medicine.

Enhancing inclusivity in clinical trials: Model-informed drug development for pregnant individuals in the era of personalized medicine.

Journal: CPT: pharmacometrics & systems pharmacology
Published: May 15, 2024
Showing 1-12 of 26

Last Updated: 09/26/2026